Literature DB >> 32500759

The clinical pharmacology of the medical treatment for overactive bladder in adults.

Hadi Mostafaei1,2, Shahrokh F Shariat1,3,4,5,6,7,8, Hanieh Salehi-Pourmehr2,9, Florian Janisch1,10, Keiichiro Mori1,11, Fahad Quhal1,12, Sakineh Hajebrahimi2.   

Abstract

INTRODUCTION: Overactive bladder is a prevalent symptom complex that affects the patient's quality of life. Any disruption between the neuronal micturition pathway can lead to bladder overactivity. Neurogenic causes, myogenic causes, aging, bladder outlet obstruction, sex, and psychological factors are some of the factors contributing to bladder overactivity. The complaint of any symptoms of OAB, which is highly prevalent and affects overall QOL, often needs therapeutic interventions. When conservative therapy methods fail, the addition of medications is recommended. The most commonly used agents for the treatment of OAB are antimuscarinic drugs. New classes of drugs, such as beta-3 agonists, have enriched our pharmacologic armamentarium. AREAS COVERED: In this review, with a special focus on oral pharmacological treatments, we discussed the definition, etiology, symptoms, diagnosis, and management of OAB. EXPERT OPINION: OAB is a multifactorial condition with every patient presenting with a different collection of symptoms and signs. Medical therapies should be given in conjunction with behavioral therapies. Using high or low doses, flexible doses, and stopping or changing the medications are interchangeable strategies based on the level of treatment efficacy and patient satisfaction.

Entities:  

Keywords:  Pharmacotherapy; antimuscarinics; botulinum toxin-A; medical treatment; overactive bladder; β-adrenoceptor agonists

Mesh:

Substances:

Year:  2020        PMID: 32500759     DOI: 10.1080/17512433.2020.1779056

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  3 in total

1.  Injectable, Adhesive, and Self-Healing Composite Hydrogels Loaded With Oxybutynin Hydrochloride for the Treatment of Overactive Bladder in Rats.

Authors:  Peng Sun; Zheng Wang; Tong Wu; Shishuai Zuo; Xiaoyu Huang; Zilian Cui; Dong Zhang
Journal:  Front Bioeng Biotechnol       Date:  2022-06-27

Review 2.  Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.

Authors:  Vincent Sauzeau; Julien Beignet; Christian Bailly
Journal:  Biomedicines       Date:  2022-06-08

Review 3.  Drug Delivery Approaches for Managing Overactive Bladder (OAB): A Systematic Review.

Authors:  Zara Khizer; Amina Sadia; Raman Sharma; Samia Farhaj; Jorabar Singh Nirwan; Pratibha G Kakadia; Talib Hussain; Abid Mehmood Yousaf; Yasser Shahzad; Barbara R Conway; Muhammad Usman Ghori
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.